Abnormalities in the function of transmembrane proteins are associated with a number of diseases. They are also important drug targets, with approximately 50% of drugs targeting transmembrane proteins. However, low expression, in vitro insolubility, unstable purification, and difficulty in maintaining natural conformation have limited their use in drug development.
Sino Biological is focused on developing multi-pass transmembrane protein products and has set up three platforms to provide important raw materials for early-stage drug development. These platforms include virus-like particles (VLP), detergent micelle, and nanodisc. Sino Biological offers custom services in addition to supplying multipass transmembrane proteins (4 pass: Claudin-6, Claudin-9, Claudin-18.1, Claudin-18.2; 7 pass: GPRC5D, CXCR4, and SSTR2) through these platforms.